Active substance | tremelimumab |
Holder | AstraZeneca AB |
Status |
Running |
Indication | as first-line treatment in patients with unresectable hepatocellular carcinoma in combination with Durvalumab (Imfinzi) |
Public documents | Approbation |
Approbation amendment | |
Information for the patient | |
Informed consent | |
Last update | 27/06/2023 |